An international study carried out with involvement of the MedUni Vienna is giving hope to patients with advanced prostate cancer.
In just a few years’ time, Ipilumumab could be approved as a treatment for the world’s third-most common type of cancer.
The immunotherapeutic agent Ipilumumab has been shown to have a markedly positive effect in the treatment of patients who are resistant to conventional hormone treatments and chemotherapy. These are the words of a core statement from a study, recently published in the highly respected journal “The Lancet Oncology”, which was set up based on collaboration between the world’s leading centres for the research and treatment of prostate cancer.
The scientists investigated the extent to which immunotherapy with this agent is also suitable for the more common type of advanced prostate cancer. The medication is already being successfully used as immunotherapy for advanced melanoma – a comparatively rare type of cancer.
Read more . . .
The Latest on: Immunotherapy
[google_news title=”” keyword=”Immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Immunotherapy
- Novel immunotherapy shows promise for high-risk sarcomas: HEROS 2.0 trial results publishedon April 24, 2024 at 11:18 pm
Researchers at Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist published results of a phase I ...
- Health Spotlight | Immunotherapy targets brain canceron April 24, 2024 at 8:03 pm
Glioblastoma is the most common and aggressive forms of brain cancer. More than 14,000 people will be diagnosed in 2024.
- GV20 Therapeutics Announces Publication in Cell Highlighting the Discovery of IGSF8 as an Innate Immune Checkpoint and Cancer Immunotherapy Targeton April 24, 2024 at 5:00 am
GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and cancer biology to create next-generation antibody therapeutics, today announced the publication of a ...
- Immunotherapy Combination Approved for Non-Muscle Invasive Bladder Canceron April 24, 2024 at 2:43 am
FDA approves immunotherapy drug combo for non-muscle invasive bladder cancer after UCLA-led research shows improved outcomes for patients.
- Scientists making progress in less toxic cancer treatment called immunotherapyon April 22, 2024 at 3:03 pm
Scientists are making progress in using less toxic immunotherapy instead of traditional chemotherapy to fight cancer.
- Improving cancer immunotherapy by prolonging T-cell survivalon April 22, 2024 at 1:20 pm
In the past decade, immunotherapy has emerged as the fourth pillar of cancer treatment, joining surgery, radiotherapy and chemotherapy. It is an approved treatment for 15 cancers, including melanoma ...
- Engineered peptides show promise in cancer immunotherapyon April 22, 2024 at 6:49 am
In a new study published today in Nature Biomedical Engineering, researchers at The University of Texas MD Anderson Cancer Center have designed a new method for developing immunotherapy drugs using ...
- Has Immunotherapy Found Its Place in Pancreatic Cancer?on April 22, 2024 at 4:09 am
A new study suggested that adding nivolumab to neoadjuvant treatment improves outcomes in patients with borderline resectable pancreatic cancer.
- Immunotherapy Developed To Localize Cancer-Killing Moleculeson April 22, 2024 at 2:12 am
A new immunotherapy has been developed that localizes cytokines to tumors for weeks while preserving their activity.
- Immunotherapy Safely Boosted with Particle-Bound Cytokines in Tumor Modelson April 21, 2024 at 10:00 am
Used in combination with immune checkpoint therapy, cytokine molecules “step on the gas” to jump-start the immune system’s anticancer response.
via Bing News